Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction

Journal of Pain and Symptom Management

Volumn 44, Issue 4, 2012, Pages 604-607

  Kaneishi, Keisuke ^a   Kawabata, Masahiro ^a   Morita, Tatsuya ^b,c  

^a TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^b Palliative Care Team ^*  (Japan)

^c SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

Advanced cancer; Incomplete bowel obstruction; Nausea; Olanzapine; Vomiting

Indexed keywords

BETAMETHASONE; OLANZAPINE;

ADULT; ADVANCED CANCER; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INCOMPLETE BOWEL OBSTRUCTION; INTESTINE OBSTRUCTION; MALE; MEDICAL RECORD REVIEW; MORBIDITY; NAUSEA AND VOMITING; ONCOLOGY WARD; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT DURATION;

EID: 84869228161     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2011.10.023     Document Type: Article

References (13)

1. Ripamonti C, Twycross R, Baines M, et al. Clinical practice recommendations for the management of bowel obstruction in patients with endestage cancer. Support Care Cancer 2001;9:223-233. (Pubitemid 32537280)
2. Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage 2010;39:756-767.
3. Fainsinger RL, Spachynski K, Hanson J, Breura E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994;9:12-18. (Pubitemid 24061820)
4. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet 1985;2:990-993. (Pubitemid 16215450)
5. ToniniM, Cipollina L, Poluzzi E, et al. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379-390. (Pubitemid 38297106)
6. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37: 177-193.
7. Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. AWorld Health Organization project. Expert Rev Anticancer Ther 2002;2:365-376. (Pubitemid 34947112)
8. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25:485-488.
9. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002;23:526-532. (Pubitemid 34627037)
10. SrivastavaM, BritoeDellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003;25:578-582. (Pubitemid 36629280)
11. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention of chemotherapye induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:131.
12. Laval G, Girardier J, Lassauniere JM, et al. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med 2000;14: 3-10. (Pubitemid 30095220)
13. Ishigooka J, Murasaki M, Miura S. The olanzapine earlyephase II study group. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an openelabel multicenter study in Japan. Psychiatry Clin Neurosci 2001;55:353-363. (Pubitemid 32776817)